Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Hypoxia activated prodrugs Stories

2013-03-28 00:20:58

TOKYO, March 28, 2013 /PRNewswire/ -- Anaeropharma Science Inc. announced on March 28 that it has initiated a Phase I clinical trial of APS001F in patients with advanced solid tumors in the United States. The first-in-human dose-escalation trial enrolls patients with advanced and/or metastatic solid tumors whose disease is no longer considered responsive to available treatments. The trial is designed to evaluate safety, tolerability and efficacy of the study agent. About...

2012-09-13 13:34:51

It seems as if a tumor deprived of oxygen would shrink. However, numerous studies have shown that tumor hypoxia, in which portions of the tumor have significantly low oxygen concentrations, is in fact linked with more aggressive tumor behavior and poorer prognosis. It´s as if rather than succumbing to gently hypoxic conditions, the lack of oxygen commonly created as a tumor outgrows its blood supply signals a tumor to grow and metastasize in search of new oxygen sources — for...

2011-05-24 07:00:00

PALO ALTO, Calif. and AUCKLAND, New Zealand, May 24, 2011 /PRNewswire/ -- Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc. (NYSE: VAR), and Auckland UniServices Ltd. of Auckland, New Zealand, today announced that they have entered into a licensing agreement granting Centella exclusive rights to CEN-209, a novel investigational drug designed to enhance the effectiveness of radiotherapy and chemotherapy when treating solid tumors that are hypoxic--or...

2011-02-14 16:24:39

Most, if not all, solid tumors contain regions that are not well oxygenated. Tumor cells in these regions, which are known as hypoxic regions, are usually resistant to the death-inducing effects of chemotherapeutics. But now, Caroline Dive and colleagues, at Manchester University, United Kingdom, have identified a compound (ABT-737) that induces human cancer cells exposed to hypoxic conditions in vitro to undergo a form of cell death known as apoptosis. In addition, cells in hypoxic regions...

2008-09-08 09:00:08

Pro-Pharmaceuticals, Inc. (AMEX: PRW), a bio-pharmaceutical company developing proprietary polysaccharide-based therapeutic compounds in the treatment of cancer, today announced it has submitted clinical and pre-clinical data to the U.S. Food and Drug Administration ("FDA") for a pre-Investigational New Drug (IND) meeting that is scheduled for October 8th. The Company plans to present the development plan to the FDA for an anti-hypoxia drug to be used in combination with DAVANAT(R) and 5-FU...

2008-08-06 09:00:11

Pro-Pharmaceuticals, Inc. (AMEX: PRW), a bio-pharmaceutical company developing proprietary polysaccharide-based therapeutic compounds in the treatment of cancer and fibrosis, today announced that a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") is scheduled for October to present the clinical development plan for a anti-hypoxia drug to be used in combination with DAVANAT(R) and 5-FU to treat advanced solid tumors, including head and neck, breast...

2008-07-15 09:00:16

Pro-Pharmaceuticals, Inc. (AMEX: PRW), a biopharmaceutical company developing proprietary polysaccharide-based therapeutic compounds in the treatment of cancer and fibrosis, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") to define the regimen for an Oxygen-based product (EZ-646) to be used with Galactomannan-C (DAVANAT(R)) and Fluorouracil (5-FU) to treat all solid tumors, including new indications such as head & neck and...